IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1267
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$388.0B
Lars F. Jørgensen
Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in areas of haemophilia, growth disorders, and hormone replacement therapy. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = NVO ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$NVO NOVO NORDISK A S | 55 | 84 | 86 | 28 | 12.6x | 2.8x | 281.5% | 86.8% | 84.7% | 44.2% | 34.8% | 16.9% | 1.7% | 77.0x | $388.0B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
NOVO NORDISK A S (NVO) receives a "Hold" rating with a composite score of 55.0/100. It ranks #1267 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Headcount
54.4K
HQ Base
Bagsværd,
Lagging peers — losers tend to keep underperforming
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for NVO.
View All RatingsROE proxy 281.5% (sector -1.9%)
GM 85% vs sector 44%, OM 44% vs sector 3%
Capital turnover N/A, R&D intensity 16.6%
Rev growth 17%, 4yr history
Interest coverage 17.5x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate NOVO NORDISK A S (NVO) as a Hold with a composite score of 55.0/100 at a current price of $38.79. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
NOVO NORDISK A S holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 55.0/100 places it at rank #1267 in our full universe.
Wide
Medium
Exemplary
Undervalued
Gross margins of 85% signal strong pricing power.
Returns on equity of 281.5% exceed cost of capital.
Value factor score of 86 suggests attractive pricing.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
NOVO NORDISK A S represents a hold based on multi-factor quantitative performance.
Our model assigns NOVO NORDISK A S a Hold rating, with a composite score of 55.0/100 and 3 out of 5 stars. Ranked #1267 of 7,333 stocks, NVO presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
NVO earns a quality score of 84/100, indicating above-average business quality. The company reports a return on equity of 281.5% (sector avg: -1.9%), gross margins of 84.7% (sector avg: 44.1%), net margins of 34.8% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
NVO carries a solid value score of 86/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 12.59x, an EV/EBITDA of 2.76x, a P/B ratio of 10.59x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
With an investment score of 41/100, NVO exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 16.9% vs. a sector average of 6.7% and a return on assets of 86.8% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
NOVO NORDISK A S is experiencing notably weak momentum with a score of just 28/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 16.9% year-over-year, while a beta of 0.97 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
With a stability score of 54/100, NVO exhibits average financial resilience. Key stability metrics include a beta of 0.97 and a debt-to-equity ratio of 77.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 55/100 for NVO suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 77.00x). With a $388.0B market cap (mega-cap), NOVO NORDISK A S may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
NVO offers a modest dividend yield of 1.7%. While the income contribution is relatively small, even a small dividend signals management's commitment to shareholder returns and can serve as a signal of financial discipline.
NOVO NORDISK A S is a mega-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1267 of 7,333 overall (83rd percentile). Key comparisons include ROE of 281.5% exceeding the -1.9% sector median and operating margins of 44.2% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While NVO currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Value (86) vs Momentum (28) — closing this gap could shift the rating.
EV/EBITDA 76% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 14917% BELOW SECTOR MEDIAN
Gross Margin 92% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
Company gains exclusive mainland China rights to ecnoglutide, approved for diabetes and under obesity review.
Viking Therapeutics' weight-loss drug candidate VK2735 has posted strong mid-stage data and is in phase 3 clinical trials, positioning it as a potential disruptor in the rapidly growing obesity drug market. While the stock could deliver outstanding returns if it successfully navigates clinical and regulatory hurdles, investors should be aware of significant risks including potential clinical setbacks and increased market competition.
Novo Nordisk stock has fallen 67% from its 2024 peak to around $47/share, but the author sees this as a buying opportunity similar to five years ago when the GLP-1 craze began. The company has regained market leadership with FDA-approved oral versions of Wegovy and Ozempic, though Eli Lilly is expected to launch competing pills in Q2 2026. Trading at a below-market price-to-free-cash-flow ratio of less than 23 with 17.5% projected FCF growth and a 3.8% dividend yield, the author recommends buying and holding the stock long-term.
Despite a 35% stock decline over the past six months due to competition concerns, Veeva Systems remains a solid long-term buy. The company's specialized cloud services for life sciences companies create strong switching costs and competitive advantages. With a goal to double revenue to $6 billion by 2030 and a history of meeting targets, Veeva is well-positioned to capitalize on the expanding life sciences industry.
Drugmaker Novo Nordisk plans to slash list prices for its wildly popular weight-loss and diabetes drugs Wegovy and Ozempic by as much as 50%, according to a report.